- Oriva Therapeutics is launched with the support of Asabys, focused on developing innovative therapies in women’s health
- The company incorporates two advanced assets from Oncostellae and Medibiofarma, addressing two high-unmet-need chronic conditions in women: endometriosis and uterine fibroids
- Sabadell Asabys II has seeded the company, and the funds will be used to advance the clinical development of the company’s programs
Oriva Therapeutics, a women’s health company developing first-in-class and best-in-class approaches to treat chronic, prevalent conditions affecting women, announced today its incorporation, as well as the successful closing of an undisclosed pre-seed financing from Asabys’ fund Sabadell Asabys II.
Oriva Therapeutics has spun off two advanced assets from Oncostellae and Medibiofarma, positioning the company as one of the first clinical-stage biotechnology companies in Spain with pure focus on the development of innovative medicines to treat chronic gynaecological diseases. The first asset, ORV-362, is a non-hormonal, disease-modifying, first-in-class therapy for endometriosis, a condition affecting approximately 10% of women and girls in reproductive age worldwide. ORV-362 is compatible with conception and has demonstrated a favourable safety profile in clinical trials conducted by the originating company. The program has entered Phase I in healthy women in January 2026. The second program, ORV-499, is focused on the treatment of uterine fibroids, the most common gynaecological benign tumours, and it is expected to enter Phase I trials in Q1 2027. Both assets target validated therapeutic pathways and leverage novel chemistry that clearly differentiates them from the competition.
This financing by Asabys will allow Oriva Therapeutics to establish the initial team and facilities and to reach Phase 2 clinical trials.
Asabys has successfully backed several other spin-offs and early-stage companies such as Ona Therapeutics, Origo Biopharma, SpliceBio, Inbrain Neuroelectronics, Nuage Therapeutics, OrikineBio and ALLOX.
Julio Castro, co-founder of Oncostellae and Medibiofarma, comments: “We are extremely pleased of having closed this innovative deal with Asabys. The two assets generated and developed within the parent companies will find a new life at Oriva, with the huge advantage of fresh financing and a novel therapeutic focus”.
Clara Campàs, Managing Partner at Asabys, mentions: “Chronic gynaecological diseases such as endometriosis and uterine fibroids have been historically underfunded
and underserved, despite their profound impact on women’s health. We are excited to support Oriva to advance these first and best-in-class programs into the clinic and ultimately to patients. The significant unmet medical need, combined with the renewed interest from the pharmaceutical industry in chronic women’s health indications and the outstanding chemistry developed by Julio Castro and his team, makes Oriva a highly promising investment for Sabadell Asabys II”.
About Oriva Therapeutics
Oriva Therapeutics is a clinical-stage women’s health biotechnology company focused on the development of first-in-class and best-in-class therapies for chronic, prevalent gynecological diseases with high unmet medical need. Based in Barcelona, the company has been created to advance innovative and disease-modifying approaches that aim to improve both clinical outcomes and quality of life for women. Oriva Therapeutics’ pipeline is built around two advanced programs in endometriosis and uterine fibroids, leveraging novel chemistry targeting validated biological pathways and differentiated from existing treatment options. The company was seeded by Sabadell Asabys II, a fund managed by Asabys Partners, and is backed by assets originating from Oncostellae and Medibiofarma.
About Asabys Partners
Asabys Partners is a Barcelona-based venture capital firm focused on innovation in healthcare and life sciences, including biopharma, medical technology, and digital health. Founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, the firm is backed by Alantra and supported by Banc Sabadell as anchor investor. Asabys aims to support highly innovative and transformative technologies that address unmet medical needs. The firm manages over €400 million in assets and 24 portfolio companies. Asabys positions itself not only as an investor but as an active and collaborative partner to its portfolio companies, with the goal of translating disruptive science into meaningful outcomes for patients. The investment in the company comes from its vehicles Sabadell Asabys Health Innovation Investments II, FCR, and Sabadell Asabys Health Innovation Investments 2B, SCR SA.
www.asabys.com
About Oncostellae
Oncostellae is a Galician clinical-stage biopharmaceutical company focused on discovering and developing proprietary therapies for areas of high unmet medical need in immunology, oncology, and gynaecological diseases. Founded in 2013 in Santiago de Compostela and supported by a strong base of private and institutional investors, the company combines deep scientific expertise with an extensive international network to advance novel drug candidates from concept through Phase I/II clinical development. Following the spin-out of its Women’s Health program to Oriva Therapeutics, Oncostellae is now concentrating on the advancement of its lead asset, OST-122, into a confirmatory Phase 2b clinical trial. OST-122 is a safe and effective gut-restricted therapy for the treatment of Inflammatory Bowel Disease (IBD).
Oncostellae is supported by leading Spanish investors like XesGalicia, Unirisco, Bio&Tech Smart Capital FCRE (Noso Capital) and Inveready.
About Medibiofarma
Medibiofarma is a Navarrese biopharmaceutical company founded in 2016, devoted to the discovery and development of novel drugs targeting validated molecular targets, with the aim of improving the lives of patients suffering from neurological, gastrointestinal and gynecological diseases. Medibiofarma has developed three projects in its pipeline to early clinical stage, in different therapeutic areas. Following the spin-out of its Women’s Health program to Oriva Therapeutics, Medibiofarma is now concentrating on the advancement of its clinical development programs in neurological and fibrostenotic diseases.
Medibiofarma is supported by leading Spanish investors like Sodena, a limited company of the Government of Navarra and Inveready.
